Episode Details
Back to Episodes
Repligen Crushes Q1, Boosts Guidance
Description
Repligens Q1 earnings soared, with $194.3M revenue, 14.8% YoY growth, and EPS of $0.48, exceeding estimates. Analytics led growth, with strong Asia demand, particularly China. Full-year guidance adjusted, with revised revenue midpoint and EPS increase. Margins expanded due to product mix and cost controls. Analysts questioned margin gains, biotech spending recovery, and China boom. Management highlighted capital equipment demand and organic revenue growth. Future focus on analytics adoption, efficiency moves, and biotech funding.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/abf18fdd41bddd50